In addition, gemcitabine-based combination chemotherapy is the most effective method for the treatment of pancreatic cancer, but there is no unified standard for which drug to combine with.7 Erlotinib is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that can inhibit tumor growth, which is often used clinically to treat advanced EGFR-mutant lung adenocarcinoma.8 In this study, a prospective cohort study was used to evaluate the clinical efficacy of erlotinib combined with concurrent chemoradiotherapy for locally advanced pancreatic cancer. The gene discussed is EGFR; the disease is lung adenocarcinoma.